Published on: 18 January 2026

Coronary Artery Calcium: A Powerful Tool in Risk Stratification for Obesity Treatment

Obesity remains a growing global health challenge, intricately linked to cardiovascular disease and reduced lifespan. In recent years, semaglutide has emerged as a potent anti-obesity agent with demonstrated cardiovascular benefits. However, its widespread use faces barriers such as high cost and limited availability. This scenario calls for strategic approaches to optimize therapy allocation. Here, coronary artery calcium (CAC) scoring shines as a promising method to stratify cardiovascular risk and identify patients who would derive the greatest benefit from semaglutide therapy.

CAC scoring, derived from non-contrast cardiac CT, offers a reliable estimate of subclinical coronary artery disease. The “power of zero” concept highlights its strong negative predictive value. Conversely, elevated CAC scores indicate higher risk, signaling the need for intensified preventive interventions. By integrating CAC into obesity management, clinicians can refine cardiovascular risk assessment beyond traditional models, tailoring semaglutide therapy to those who stand to gain the most.

Real-World Evidence: Linking CAC Scores with Cardiovascular Events in Obese Adults

A comprehensive analysis of over 38,000 semaglutide-eligible individuals without established cardiovascular disease revealed a clear, graded relationship between CAC scores and adverse cardiovascular events. Participants with CAC scores above 400 exhibited nearly double the risk of major cardiovascular events, heart failure, and all-cause mortality compared to those with a CAC of zero.

This stratified risk underscores the utility of CAC in primary prevention settings, particularly among obese adults. Notably, higher CAC scores correlated with traditional risk markers such as older age, male sex, and hypertension, reinforcing its role as an integrative risk marker. These findings emphasize that CAC scoring can efficiently identify obese patients at elevated cardiovascular risk who might benefit most from aggressive interventions like semaglutide therapy.

Semaglutide Therapy: Projected Clinical Benefits Amplified by CAC-Guided Selection

Modeling semaglutide use over a 3.3-year period demonstrated a marked increase in absolute risk reduction across CAC strata. The number needed to treat (NNT) to prevent one major adverse cardiovascular event dropped significantly from 151 in individuals with zero CAC to just 34 in those with CAC scores ≥400. Similarly, reductions in heart failure and all-cause mortality reflected this trend.

These results suggest that CAC scoring can serve as a crucial decision-making tool, optimizing semaglutide allocation. By focusing treatment on those with elevated CAC, clinicians may maximize clinical outcomes while avoiding unnecessary exposure in low-risk patients. Moreover, this risk-based approach aligns with precision medicine principles, enhancing therapeutic efficiency in obesity management.

Economic Considerations: Enhancing Cost-Effectiveness Through CAC Risk Stratification

Despite semaglutide’s clinical promise, its high cost challenges healthcare systems worldwide. Cost-effectiveness analysis using lifetime Markov models revealed that incremental cost-effectiveness ratios (ICERs) improve substantially with increasing CAC scores. For patients with no detectable CAC, ICERs exceeded $600,000 per quality-adjusted life year (QALY), indicating limited economic feasibility. In contrast, for those with CAC ≥400, ICERs dropped to approximately $170,000 per QALY.

Although these figures remain above typical willingness-to-pay thresholds, CAC-based targeting significantly enhances semaglutide’s economic value. Sensitivity analyses further showed that reducing semaglutide’s annual cost to around $4,000 markedly improves cost-effectiveness in high-risk groups. Therefore, integrating CAC scoring into clinical pathways may support more judicious use of semaglutide, balancing clinical benefits with fiscal responsibility.

Practical Implications for Healthcare Professionals: Toward Equitable and Effective Weight Management

Healthcare professionals managing obesity face the dual challenge of improving patient outcomes while navigating resource constraints. The incorporation of CAC scoring offers a pragmatic strategy to prioritize semaglutide therapy. By identifying patients at greatest cardiovascular risk, clinicians can tailor treatment, potentially reducing health disparities and improving overall care efficiency.

Furthermore, CAC-guided semaglutide allocation aligns with the growing emphasis on personalized medicine and value-based care. It equips healthcare providers with evidence-based criteria to optimize therapeutic decisions, thereby enhancing patient safety and maximizing return on investment. As obesity prevalence rises globally, such approaches become indispensable for sustainable healthcare delivery.

Conclusion: Harnessing CAC Scoring to Revolutionize Obesity Treatment Paradigms

In summary, coronary artery calcium scoring emerges as a vital tool to enhance risk stratification among obese adults eligible for semaglutide therapy. Real-world data affirm its association with cardiovascular event risk, while modeling studies highlight improved clinical benefit and cost-effectiveness with CAC-guided treatment. For healthcare professionals, integrating CAC assessment into obesity management protocols promises to optimize semaglutide use, improve patient outcomes, and promote efficient healthcare spending. This strategy represents a forward-thinking approach in global Muslim weight management and beyond, fostering equitable and precision-based obesity care.

Source: https://doi.org/10.1111/dom.70515

LEARN MORE ABOUT THE MUSLIM WEIGHT MANAGEMENT